The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradio...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Dan, Li, Baosheng, Zhao, Qian, Sun, Hongfu, Dong, Jinling, Hao, Shaoyu, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333126/
https://www.ncbi.nlm.nih.gov/pubmed/35912182
http://dx.doi.org/10.3389/fonc.2022.890688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333126/
https://www.ncbi.nlm.nih.gov/pubmed/35912182
http://dx.doi.org/10.3389/fonc.2022.890688

Ejemplares similares